Foundation Fighting Blindness
17
2
7
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
5.9%
1 terminated/withdrawn out of 17 trials
88.9%
+2.4% vs industry average
0%
0 trials in Phase 3/4
50%
4 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
Role: collaborator
Rate of Progression in EYS Related Retinal Degeneration
Role: collaborator
Rate of Progression in USH2A-related Retinal Degeneration
Role: collaborator
Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F
Role: collaborator
Gyrate Atrophy Ocular and Systemic Study
Role: collaborator
Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome
Role: collaborator
Inherited Retinal Degenerative Disease Registry
Role: lead
The Dark-Adapted Retinal Function Response in Choroideremia (DARC) Study
Role: collaborator
An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia
Role: collaborator
A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
Role: lead
Trial of Oral Valproic Acid for Retinitis Pigmentosa
Role: lead
Clinical Evaluation of Patients With X-linked Retinoschisis
Role: collaborator
Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD
Role: collaborator
Observational Study of the Argus® II Retinal Prosthesis System
Role: collaborator
DHA and X-Linked Retinitis Pigmentosa
Role: collaborator
Safety Study in Retinal Transplantation for Dry Age Related Macular Degeneration.
Role: collaborator
Safety Study in Retinal Transplantation for Retinitis Pigmentosa.
Role: collaborator
All 17 trials loaded